Shares of ATRION Co. (NASDAQ:ATRI) have received a consensus broker rating score of 5.00 (Strong Sell) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong sell rating.
Analysts have set a 1 year consensus target price of $300.00 for the company, according to Zacks. Zacks has also given ATRION an industry rank of 204 out of 265 based on the ratings given to related companies.
Separately, BidaskClub downgraded ATRION from a “sell” rating to a “strong sell” rating in a research report on Saturday, April 7th.
ATRION (NASDAQ:ATRI) last announced its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $4.66 earnings per share for the quarter. ATRION had a return on equity of 19.53% and a net margin of 24.96%. The firm had revenue of $34.02 million during the quarter.
The business also recently disclosed a quarterly dividend, which was paid on Friday, March 30th. Shareholders of record on Thursday, March 15th were given a $1.20 dividend. The ex-dividend date of this dividend was Wednesday, March 14th. This represents a $4.80 annualized dividend and a yield of 0.79%.
A number of hedge funds have recently made changes to their positions in the business. California Public Employees Retirement System lifted its position in ATRION by 2.1% in the third quarter. California Public Employees Retirement System now owns 4,188 shares of the medical instruments supplier’s stock valued at $2,814,000 after purchasing an additional 88 shares during the last quarter. Advisor Group Inc. raised its holdings in shares of ATRION by 11.6% during the fourth quarter. Advisor Group Inc. now owns 992 shares of the medical instruments supplier’s stock valued at $625,000 after acquiring an additional 103 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of ATRION by 1.7% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 6,972 shares of the medical instruments supplier’s stock valued at $4,397,000 after acquiring an additional 115 shares in the last quarter. Bank of Montreal Can raised its holdings in shares of ATRION by 25.7% during the fourth quarter. Bank of Montreal Can now owns 597 shares of the medical instruments supplier’s stock valued at $376,000 after acquiring an additional 122 shares in the last quarter. Finally, Pennsylvania Trust Co raised its holdings in shares of ATRION by 2.0% during the fourth quarter. Pennsylvania Trust Co now owns 9,895 shares of the medical instruments supplier’s stock valued at $6,240,000 after acquiring an additional 195 shares in the last quarter. Hedge funds and other institutional investors own 59.05% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://dakotafinancialnews.com/2018/04/12/zacks-atrion-co-atri-given-300-00-average-price-target-by-brokerages.html.
ATRION Company Profile
Atrion Corp. engages in the manufacture and development of products for medical applications. It involves in the marketing of components to other equipment manufacturers for incorporation in their products and sell finished devices to physicians, hospitals, clinics and other treatment centers. It specializes in the fluid delivery, as well as ophthalmic and cardiovascular devices.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ATRION Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ATRION and related companies with MarketBeat.com's FREE daily email newsletter.